Congress quietly doubles funding for sickle cell research
S. 735 — Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2025 · Filed by Tim Scott (R-SC) · 3 cosponsors · Introduced Feb 26, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill reauthorizes and expands a federal program that funds research, treatment, and prevention of sickle cell disease and related blood disorders. It increases annual funding from $4.5 million to $8.2 million for fiscal years 2025–2029, broadens the program to include prevention of complications (not just the disease itself), and allows grants in addition to contracts. The bill benefits patients with sickle cell disease, researchers, and treatment providers by increasing resources for a disease that disproportionately affects Black Americans.
Why we flagged it
The bill's sole operative mechanism is reauthorization and expansion of a federal research and treatment program for a specific disease. It is straightforward public health legislation with no hidden provisions or private carve-outs.
What the text implies
- Shift from 'prevention and treatment' to 'treatment and prevention of complications' may subtly narrow focus from primary prevention (e.g., genetic counseling, carrier screening) to clinical management of existing disease, though the practical impact depends on implementation.
- Expansion to 'heritable blood disorders' beyond sickle cell (e.g., thalassemia, hemophilia) is stated in the sense-of-Congress clause but not explicitly funded in the reauthorization amount, creating potential ambiguity about whether the $8.2M covers both or primarily sickle cell.
- Grant authority (in addition to contracts) may increase flexibility but could also reduce accountability if grants are awarded without competitive bidding requirements that typically apply to contracts.
Who it affects
The bill increases federal funding for research and treatment of a serious genetic disease affecting a vulnerable population, expands the scope of supported interventions, and creates no new restrictions on citizens or public benefits. The primary effect is to expand public health capacity and research resources.
Who stands to gain
- academic medical centers and research institutions
- sickle cell disease treatment and research organizations
- public health agencies and state health departments
Named in the bill
Senate Committee on Health, Education, Labor, and Pensions, Public Health Service Act, Section 1106(b) of the Public Health Service Act, sickle cell disease, heritable blood disorders
Where it stands
3 cosponsors: 3 Democrats.
- Feb 26, 2025 — Introduced · Congress.gov: “Introduced in Senate”
- Feb 26, 2025 — Referred to Senate Committee on Health, Education, Labor, and Pensions · Congress.gov: “Read twice and referred to the Committee on Health, Education, Labor, and Pensions”
Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.
Money around this bill
3 lobbying clients named this bill on 4 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $140,000 in lobbying spend. A filing names 4 bills on average, so that figure is what each filing reported, not a share belonging to this bill.
More lobbying clients named this bill than 61% of bills with at least one filing.
Tim Scott, the sponsor, reported $214,300 in PAC receipts in the 2026 cycle.
- Fulcrum Therapeutics — $60,000 on 1 filing
- Sick Cells — $60,000 on 2 filings
- Terumo Bct, Inc. — $20,000 on 1 filing
Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.
How this was measured
Analysis — Quorum's AI scored this bill from its title only — the full text has not been read; transparency and hidden-provision scores are compared against the median of 16,222 analysed bills.
Status and sponsors — Congress.gov's bill record — actions, committee referrals and cosponsors — loaded nightly. The timeline shows status changes, not every procedural action.
Money — Senate Lobbying Disclosure Act filings whose specific-issue field names this bill for quarters ending Dec 2025 to Jun 2026. A filing's amount is reported whole beside the median number of bills a filing names; it is never divided across them. PAC receipts are FEC-reported contributions to the sponsor's candidate committee in the 2026 cycle.
As of — lobbying records through Jul 20, 2026 · page rendered 2026-10-20.
“Congress quietly doubles funding for sickle cell research” QuorumCivic. https://share.quorumcivic.app/bill/119/s735 Report an error
The week in bills
One email, Sunday: what Congress passed, what it changed, and who paid.
One link arrives to confirm the address. It is used for this email and nothing else, and every issue carries an unsubscribe link.